검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Bispecific antibody |
Overview Company | Sung-Soo Park |
Overview Modality | ANTIBODY |
Overview Target | FRα |
Overview Indication | Multiple Myeloma, Relapsed; Multiple Myeloma (MM) |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
MoA Mechanism | targeting CD16 and the epidermal growth factor receptor |
MoA Biomarker | BCMA) is a high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Elranatamab: A novel B-cell maturation T-cell engager.. B-cell maturation antigen (BCMA) is a highly expressed transmembrane receptor on malignant plasma cells, mediating cell survival. These characteristics make it an attractive target for novel cellular and immunotherapies. Elranatamab is a bispecific antibody targeting BCMA on plasma cells and CD3 on T cells. This leads to immune cell activatio… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 11.1% |
Clinical ORR | 11.1% |
Clinical Result source | ClinicalTrials.gov NCT03340766 |
Clinical Data Tier / Score | A · 28 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Bispecific antibody |
Overview Company | Sung-Soo Park |
Overview Modality | ANTIBODY |
Overview Target | FRα |
Overview Indication | Multiple Myeloma, Relapsed; Multiple Myeloma (MM) |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
MoA Mechanism | targeting CD16 and the epidermal growth factor receptor |
MoA Biomarker | BCMA) is a high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Elranatamab: A novel B-cell maturation T-cell engager.. B-cell maturation antigen (BCMA) is a highly expressed transmembrane receptor on malignant plasma cells, mediating cell survival. These characteristics make it an attractive target for novel cellular and immunotherapies. Elranatamab is a bispecific antibody targeting BCMA on plasma cells and CD3 on T cells. This leads to immune cell activatio… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 11.1% |
Clinical ORR | 11.1% |
Clinical Result source | ClinicalTrials.gov NCT03340766 |
Clinical Data Tier / Score | A · 28 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교